EsoCap Investment Offer
EsoCap AG (‘EsoCap’) is offering an equity investment of CHF 10 million in a private placement at a price of CHF 28 per share, representing a pre-money valuation of CHF 77.5 million.
The funds from this offering will be used for the roll-out of the international patent portfolio, preparation of the pivotal Phase III clinical trial, interactions with regulatory authorities in the US and Europe, industrial scale-up and production of clinical trial material for the Phase III clinical trial.
EsoCap is in the process of preparing a commercial transaction with a major pharmaceutical company specialising in gastroenterology and cancer. EsoCap is in the process of preparing a commercial transaction with a major pharmaceutical company specialising in gastroenterology and cancer. EsoCap's technology platform has the potential to unlock breakthrough treatment options for over 370 million patients in a market worth more than USD 10bn. EsoCap is thus an extremely attractive target for commercial transactions.
About EsoCap
EsoCap AG is a privately funded joint stock company based in Basel, Switzerland.
EsoCap has successfully developed a unique, highly sophisticated platform technology with multiple applications for local drug therapy in patients with severe oesophageal diseases.
EsoCap's technology guarantees a significantly longer contact time of drugs (small molecules, peptides, biologics, and encapsulated mRNA treatment principles) in the oesophagus, resulting in a safe and highly effective treatment outcome.
The lead candidate ESO-101 has received Orphan Drug Designation from the US Food & Drug Administration (FDA) for the treatment of eosinophilic oesophagitis (EoE). EsoCap recently successfully completed the double-blind, randomised, placebo-controlled Phase II ACESO study with ESO-101 in five countries, demonstrating the clinical applicability of the platform technology.
EsoCap has a strong and diversified intellectual property position as well as a highly complementary team and development infrastructure.
For more information, please visit www.esocapbiotech.com
Contact:
Isabelle Racamier
CEO
isabelle.racamier@esocapbiotech.com
Phone: +43 699 149 50 300
|
Investor lunch presentation
On October 24th, 2024 there will be a lunch presentation in Zurich at Club zum Rennweg.
If you like to attend, RSVP here or send an email.
We are looking forward to seeing you.
|
|
|
|